6 Important Facts about Koselugo® (selumetinib) for Treating Physicians

Watch this video to learn about the first and only FDA-approved therapy proven to shrink NF1 PN in pediatric patients. You’ll also see data on onset of response and duration of response.
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS associated with Koselugo (selumetinib) include Cardiomyopathy, Ocular Toxicity, Gastrointestinal Toxicity, Skin Toxicity, Increased Creatine Phosphokinase, Increased Levels of Vitamin E and Risk of Bleeding, and Embryo-Fetal Toxicity.
ADVERSE REACTIONS (greater than or equal to 40%) include vomiting, rash (all), abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, pyrexia, acneiform rash, stomatitis, headache, paronychia, and pruritus.
DRUG INTERACTIONS include strong/moderate CYP3A4 Inhibitors or Fluconazole and CYP3A4 Inducers.
Please see additional Important Safety Information throughout and full Prescribing Information for Koselugo (selumetinib) at alexion.com/Do....
This content is intended for US HCP audiences only. © 2024, Alexion Pharmaceuticals, Inc. All rights reserved. Source file job code US/KOS-NF1/0612